AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Quoin Pharmaceuticals Ltd. Statistics
Share Statistics
Quoin Pharmaceuticals Ltd. has 5.49M shares outstanding. The number of shares has increased by 37% in one year.
Shares Outstanding | 5.49M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 26.88% |
Owned by Institutions (%) | n/a |
Shares Floating | 3.88M |
Failed to Deliver (FTD) Shares | 6.61K |
FTD / Avg. Volume | 0.19% |
Short Selling Information
The latest short interest is 19.17K, so 0.38% of the outstanding shares have been sold short.
Short Interest | 19.17K |
Short % of Shares Out | 0.38% |
Short % of Float | 0.49% |
Short Ratio (days to cover) | 0.2 |
Valuation Ratios
The PE ratio is -0.51 and the forward PE ratio is -0.51.
PE Ratio | -0.51 |
Forward PE | -0.51 |
PS Ratio | 0 |
Forward PS | 0.2 |
PB Ratio | 0.78 |
P/FCF Ratio | -0.56 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Quoin Pharmaceuticals Ltd..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.15, with a Debt / Equity ratio of 0.
Current Ratio | 3.15 |
Quick Ratio | 3.15 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.53% and return on capital (ROIC) is -165.91%.
Return on Equity (ROE) | -1.53% |
Return on Assets (ROA) | -0.71% |
Return on Capital (ROIC) | -165.91% |
Revenue Per Employee | 0 |
Profits Per Employee | -2.17M |
Employee Count | 4 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 22.38K |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -86.1% in the last 52 weeks. The beta is 1.89, so Quoin Pharmaceuticals Ltd.'s price volatility has been higher than the market average.
Beta | 1.89 |
52-Week Price Change | -86.1% |
50-Day Moving Average | 0.65 |
200-Day Moving Average | 0.66 |
Relative Strength Index (RSI) | 43.67 |
Average Volume (20 Days) | 3.49M |
Income Statement
Revenue | n/a |
Gross Profit | -103.44K |
Operating Income | -9.38M |
Net Income | -8.69M |
EBITDA | -9.27M |
EBIT | n/a |
Earnings Per Share (EPS) | -9.64 |
Balance Sheet
The company has 2.40M in cash and 3.52K in debt, giving a net cash position of 2.40M.
Cash & Cash Equivalents | 2.40M |
Total Debt | 3.52K |
Net Cash | 2.40M |
Retained Earnings | -46.20M |
Total Assets | 11.39M |
Working Capital | 7.02M |
Cash Flow
In the last 12 months, operating cash flow was -7.86M and capital expenditures 0, giving a free cash flow of -7.86M.
Operating Cash Flow | -7.86M |
Capital Expenditures | 0 |
Free Cash Flow | -7.86M |
FCF Per Share | -8.73 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
QNRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -1691.23% |
FCF Yield | -250.94% |
Analyst Forecast
The average price target for QNRX is $4, which is 601.8% higher than the current price. The consensus rating is "Buy".
Price Target | $4 |
Price Target Difference | 601.8% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 18, 2023. It was a backward split with a ratio of 1:12.
Last Split Date | Jul 18, 2023 |
Split Type | backward |
Split Ratio | 1:12 |
Scores
Altman Z-Score | -8.07 |
Piotroski F-Score | 1 |